Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by SouthernTierTomon Mar 26, 2022 6:51pm
204 Views
Post# 34548841

All the Canadien Bio-techs with unexplained NEGATIVE.....

All the Canadien Bio-techs with unexplained NEGATIVE.....20+ year bullboard programs seem to put their "Invester Updates" out on a Saturday...just an observation.  More importantly, the ones with 4 existing FDA approvals and key decisions to DE-LIST from proper US stock market listings that STUNT / HALT  news flow here to the US and  have Beech Boys that "tend the bullboard" on a 24 / 7 basis seem to "follow a similar pattern"..likely just an unexplained "coin-cie-dunse" in this particular instance ; - )

Bear in Mind, so far this year one site ( Colorado Springs ) has produced 2 patients in only month..WOW!!! "how did you do it, "how could they even handle one let alone 2 patients"? ; - )

Just remember friends..IT is ALL real, and the idea of a seasoned bored hiring a young gent to play curious accounting games whilst bringing NO obvious bio-tech experience and subsequently justifying the issuance of about 100M more shares since the curious debacle that was our phase 3 is really NOT benefitting ANYONE in ANYWAY..apparently..

Bear in mind II, that on August 22 2014 the FDA declared members or those not at an arm's length could NO longer purchase shares of then "DIAGF" and now "EDTXF" Hmmmm Wally, didn't the phase 3 Euphrates start in like 2010?  Furthermore Wally, didn't the interim data number adjustment suggest the 11 to 12% efficacy as shared by EDTXF in public at AGM events and stuff?  

I dunno Beav, I just remember 3 press releases to "spit out" the interim data AND NOT once were given the actual patient numbers or efficacy data....Important though Beav, the inner circle filled their pockets at 29 cents CAD as part of the interim analysis presentation.  "Sumthin don't sound right" Wally....You're a genuis "Beav" ; - ) ....."knock it off Wally, I'll bet they knock it out of the park"

* Disclaimer...NEVER get any financial intel from a penny stock forum.  They are designed for retial shareholders to share idea and ask questions.  In $UM cases they are designed to escort multi-decade social media RUSE's ...it is impossible to determine what this little "charade" is all about. ; - )  Furthermore, Beaver and Wally "peaked too soon" and therefore should not be used to guide any invester decisions

Bon appy,
Tom

<< Previous
Bullboard Posts
Next >>